Discover the latest innovations in structural heart devices, spanning new TAVR platforms, mitral and tricuspid valve technologies, leaflet modification, and closure devices. Gain insight into the comprehensive innovation pathway from concept and prototyping to regulatory approval and clinical adoption, with perspectives from physician-innovators on drivers of...

This session delves into the complexities of managing complications during STEMI interventions. Through real-world cases from Algeria, Malaysia, and Pakistan, it provides comprehensive analyses of challenging scenarios, treatment strategies, and key learnings, emphasizing the critical decision-making required to navigate complications and improve patient outcomes in high-stakes...

Focused on the formidable challenges posed by coronary calcium, this session presents three compelling cases illustrating complications, procedural crashes, and successful recoveries. Participants learn detailed approaches to treating PCI complications related to calcified lesions and develop a skillset aimed at prevention and effective management of these...

This multinational session highlights advanced approaches to complex PCI involving heavily calcified coronary arteries. It aims to enhance mastery of contemporary calcium modification tools, reinforce decision-making skills in high-risk, complication-prone interventions, and optimize imaging-guided assessment of coronary calcium through illustrative cases from Bulgaria, Romania, and Tunisia.

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...